- Home
- XPO vs BIIB Comparison
XPO vs BIIB Comparison
Compare XPO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPO
- BIIB
- Stock Information
- Founded
- XPO 2000
- BIIB 1978
- Country
- XPO United States
- BIIB United States
- Employees
- XPO N/A
- BIIB N/A
- Industry
- XPO Transportation Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- XPO Consumer Discretionary
- BIIB Health Care
- Exchange
- XPO Nasdaq
- BIIB Nasdaq
- Market Cap
- XPO 16.0B
- BIIB 24.2B
- IPO Year
- XPO N/A
- BIIB 1991
- Fundamental
- Price
- XPO $134.08
- BIIB $168.52
- Analyst Decision
- XPO Strong Buy
- BIIB Buy
- Analyst Count
- XPO 18
- BIIB 24
- Target Price
- XPO $145.61
- BIIB $174.62
- AVG Volume (30 Days)
- XPO 1.4M
- BIIB 1.8M
- Earning Date
- XPO 10-30-2025
- BIIB 10-30-2025
- Dividend Yield
- XPO N/A
- BIIB N/A
- EPS Growth
- XPO N/A
- BIIB N/A
- EPS
- XPO 2.78
- BIIB 10.97
- Revenue
- XPO $8,068,000,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- XPO $1.30
- BIIB $2.97
- Revenue Next Year
- XPO $3.90
- BIIB N/A
- P/E Ratio
- XPO $48.11
- BIIB $15.27
- Revenue Growth
- XPO N/A
- BIIB 4.77
- 52 Week Low
- XPO $85.06
- BIIB $110.04
- 52 Week High
- XPO $161.00
- BIIB $175.86
- Technical
- Relative Strength Index (RSI)
- XPO 49.41
- BIIB 74.64
- Support Level
- XPO $136.38
- BIIB $151.83
- Resistance Level
- XPO $142.03
- BIIB $157.79
- Average True Range (ATR)
- XPO 5.68
- BIIB 5.59
- MACD
- XPO -0.08
- BIIB 1.37
- Stochastic Oscillator
- XPO 54.69
- BIIB 95.37
About XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).